ReportWire

Tag: Medical Meetings

  • Employees with obesity may have higher loss of work productivity than those with normal weight

    Employees with obesity may have higher loss of work productivity than those with normal weight

    Newswise — CHICAGO—People with obesity may have lower work productivity due to increased risk of illness, contributing to increased costs for employers, according to industry-supported research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting, in Chicago, Ill.

    Obesity is a significant public health issue affecting approximately 42% of people in the United States. Employees with overweight or obesity are more likely to develop weight-related comorbidities such as type 2 diabetes, hypertension, sleep apnea, cardiovascular disease, and cancer, which all contribute to lower work productivity.

    “Employees with overweight and obesity may have higher loss of work productivity as measured by absenteeism, short and long-term disability, and worker’s compensation compared to employees with normal weight,” said Clare J. Lee, M.D., of Eli Lilly & Company in Indianapolis, Ind.

    Co-author Shraddha Shinde M.B.A, also of Eli Lilly & Company, added that, “Given the substantial burden of overweight and obesity on employee health and function that was demonstrated by this study, employers should focus on building tailored interventions that could be beneficial in improving the health of these individuals.”

    The researchers evaluated 719,482 employees with and without obesity in the MarketScan databases. They determined the percentage of employees with work loss, number of hours/days lost from work, and costs associated with productivity loss were higher among people with overweight or obesity. The loss of work productivity was greater with each higher Body Mass Index (BMI) category.

    The researchers found costs associated with absenteeism, short and long-term disability, and worker’s compensation were $891, $623, $41, and $112 higher per year (respectively) for people with obesity compared to those with normal weight.

    Funding for this study was provided by Eli Lilly and Company.

    # # #

    Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

    The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.

    Endocrine Society

    Source link

  • Gaps remain in identifying, treating obesity despite new treatment options

    Gaps remain in identifying, treating obesity despite new treatment options

    Newswise — CHICAGO—By being undiagnosed or untreated, a significant fraction of people with obesity or overweight are not getting the recommended care, despite an increase in new treatment options, according to research being presented on June 17 at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

    “The number of people with obesity is high and rising in the adult U.S. population. Obesity is a complex and expensive disease that has been implicated in many chronic conditions including high blood pressure, diabetes, and cardiovascular diseases,” said Kyrian Ezendu, Ph.D., an Eli Lilly and Company advisor on benefit-risk research. “Medications to treat obesity are an integral part of long-term care for people with excess weight and are recommended for people with obesity or people with overweight and at least one obesity-related condition.”

    Ezendu and colleagues used data from linked electronic health records and insurance claims of people ages 18 to 80 years who were eligible for obesity medications each year from 2016 to 2021. The anti-obesity medications included phentermine-topiramate, lorcaserin, orlistat, naltrexone-bupropion, liraglutide and semaglutide.

    There were approximately 1.6 million to 2.2 million adults with overweight or obesity, eligible for obesity medications in the study cohort for each year.

    The overall obesity diagnosis rate based on both electronic health records and claims increased from 39.4% in 2016 to 57.2% in 2021. However, diagnosis rates from insurance claims alone were only 33.5% in 2016 and 47.3% in 2021.

    Similarly, the overweight diagnosis rate grew from 18.1% in 2016 to 31.2% in 2021. Meanwhile, the claims-based rate was 15.4% in 2016 and 29.2% in 2021.

    Prescribing rates for anti-obesity medications were low, according to the researchers, ranging from 0.4% to 0.5% across all years. Much like the obesity diagnosis and overweight diagnosis rates, the prescription fill rates showed an increase from 0.4% in 2016 to 0.6% in 2021.

    Of note, the prescribing and fill rates from 2016 to 2021 for liraglutide doubled (from 0.1% to 0.2%). For semaglutide, it quadrupled (from 0.1% to 0.4%).

    “This research demonstrates a potential gap in clinical care for people with obesity and overweight. Proper documentation of the clinical diagnosis may facilitate guideline-based treatment of obesity and overweight, particularly with the availability of several FDA-approved medications for use as an adjunct to lifestyle changes in managing obesity or overweight,” Ezendu said.

    ### 

    Endocrine Society

    Source link

  • Study finds “robotic pill” can safely deliver injectable osteoporosis drug

    Study finds “robotic pill” can safely deliver injectable osteoporosis drug

    Newswise — A proven and effective medication for osteoporosis, which is currently only available as an injection, can be administered orally using a novel “robotic pill,” according to a study presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

    “We believe this study provides the first clinical evidence of safe and successful delivery of the osteoporosis drug teriparatide through an oral robotic pill,” said Arvinder Dhalla, Ph.D., who leads Clinical Development at Rani Therapeutics, the San Jose, Calif.-based company that developed the technology and funded the study. “Data from this study are very encouraging and should give hope to those suffering from chronic conditions that require painful injections, like osteoporosis, that an oral alternative could be on the way.”

    When a person swallows the robotic pill, it moves through the stomach intact. In the intestine the pill releases a self-inflating balloon with a microsyringe, which injects a drug-filled microneedle and delivers the medication.

    “The intestines do not have pain response to needles, so the injection is painless,” Dhalla said. The needle rapidly dissolves, and the medication is absorbed while the delivery mechanism deflates and is safely passed out of the body.

    “The robotic pill, which is essentially a swallowable auto-injector in the form of a pill, is designed to deliver the drug safely and efficiently as a painless intestinal injection,” she said. 

    The Phase I study of 39 healthy women evaluated the safety, tolerability and movement through the body of the robotic pill known as RT-102, containing a dose of the drug teriparatide (PTH 1-34). Teriparatide is a synthetic form of the natural human parathyroid hormone. It has been in clinical use for decades as an injectable medication (under the brand name Forteo®) for rebuilding brittle bones of osteoporosis patients. It is taken as a daily injection for up to two years.

    Study participants were divided into three groups. Two groups received either a lower or higher dose delivered with the robotic pill, and the third group received a standard injection of teriparatide. Fluoroscopic imaging was used to track the robotic pill through and out the body. Drug concentrations were measured in blood samples collected over six hours. The study found the bioavailability (the ability of the drug to be absorbed and used by the body) of the drug delivered by the robotic pill was comparable to or better than the drug given via the injection.

    “This breakthrough technology of converting injections into oral pills is a significant step forward towards ending the burden of painful injections for millions of patients suffering from chronic diseases,” Dhalla said.

    Dhalla is scheduled to present at the Society’s ENDO 2023 hormones and technology news conference at 9 AM Central on Saturday, June 17. Register to view the news conference livestream at endomediastream.com

    # # #

    Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

    The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.

    Endocrine Society

    Source link

  • Promising Phase III Results Give Hope to People Living with Myelodysplastic Syndromes

    Promising Phase III Results Give Hope to People Living with Myelodysplastic Syndromes

    Newswise — Amer Zeidan, MBBS, medical director of the hematology early therapeutics research program at Yale Cancer Center and associate professor of medicine (hematology) at Yale School of Medicine, will reveal new data at the American Society of Clinical Oncology (ASCO) annual meeting from a phase III study evaluating the efficacy of imetelstat in red blood cell (RBC) transfusion-dependent lower-risk myelodysplastic syndrome (LR-MDS) patients. Myelodysplastic syndromes(MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The study results demonstrate significant and clinically meaningful efficacy, representing a potential breakthrough in the treatment of anemic LR-MDS.

    Imetelstat, a telomerase inhibitor, was evaluated in patients who were heavily RBC transfusion-dependent LR-MDS and who were refractory or ineligible for erythropoiesis-stimulating agents (ESAs), but did not receive lenalidomide or hypomethylating agents (other drugs used to treat MDS). The phase III study, known as IMerge, enrolled a total of 178 patients. The findings from the study provide critical evidence supporting imetelstat’s efficacy and safety profile. These results are expected to have a substantial impact on future treatment strategies for patients diagnosed with LR-MDS.

    Dr. Zeidan, first and presenting author of the research at ASCO, answered questions on the study and its significance for patients living with MDS:

    Q: What is the significance of this study?

    A: “This is a very important study. Imetelstat is a first-in-class agent. It’s a first-in-class telomerase inhibitor, and this is the first time we have a phase III study of a drug in this class. We already completed the phase II study that was single arm that looked at a similar population of patients with lower risk MDS (myelodysplastic syndromes) who are heavily transfusion dependent, and the transfusion independence rate with the drug was around 40%. Transfusions in MDS are associated with increased risk of complications, increased risk of death, not to mention healthcare utilization and costs. So, trying to reduce transfusions and ideally make patients transfusion independent is a very important goal of treatment in patients with lower risk MDS.

    So the excellent activity of imetelstat in the phase II part of the study was taken to a phase III trial and what we have found in this study is what we actually expected based on the phase II trial: the transfusion dependence rate was much better with imetelstat compared to placebo, it was around 40% for an eight-week duration of transfusion dependence, the primary endpoint of the study, compared to 15% with a placebo; and most importantly, it was also durable. The median duration of transfusion independence for those who responded was more than 50 weeks. So clearly, a very positive study, very consistent with the phase II data. I think this drug could become an important option for patients.”

    Q: What are the key findings from the data? What will you highlight at ASCO?

    A: “During the ASCO presentation, we’ll discuss in detail, the efficacy of the drug in terms of transfusion independence, hematologic improvement, durability of response, but also looking within subgroups for patients based on the genetic profile. We will also discuss early signs of disease modification that we are seeing through reduction of variable allele frequency of important mutations that contribute to the pathogenesis of MDS. We’ll also discuss the side effect profile and how the interruption of therapy has led to, I think, a manageable and reversible side-effect profile, mostly in the setting of liver enzyme abnormalities and cytopenias (a medical condition where there are a low number of red blood cells).”

    Q: Are there other treatment options for this niche group of patients affected by this cancer?

    A: “Yes, so myelodysplastic syndromes have been renamed neoplasms by the World Health Organization, the most recent classification to emphasize that it’s a cancer. Many people think of MDS as an anemia or a pre-leukemia or a syndrome, but they are actually cancers. However, they differ in their severity. Patients in general are grouped into two big groups, lower risk and higher risk. In lower risk patients, those patients can live for years, but they have a lot of complications related to the low blood counts. That could be anemia, thrombocytopenia, or neutropenia, or a combination of these, but the most common use cytopenia is anemia. Anemia often is associated with reduced quality of life. The patient often needs regular transfusions. It’s also associated with significant complications and high risk of death, as well as issues related to needing to go to the clinic frequently, healthcare utilization costs. Correction of anemia is very important. Historically, the only treatment we had was erythropoiesis stimulating agents for patients with lower risk MDS. In recent years, other drugs have been approved like lenalidomide, as well as hypomethylating agents and luspatercept. However, the response to these drugs is limited, and at some point, the patient will progress and will need additional treatment. I think imetelstat potentially could fill a very important gap there because those patients are generally not going to be cured without a bone marrow transplant, which is not something that’s commonly done in MDS patients where the average age is in the early 70s. The goal is to try to improve quality of life in those lower risk MDS patients and make them transfusion independent as much as possible and that’s generally achieved by sequential therapy. So you go from one agent to the next, while trying to maintain quality of life keeping the patient out of the hospital and minimizing complications of the treatment itself.”

    Q: What is next in terms of research. What would you like done in future studies?

    A: “This is a very important question. I think the next step is going to be focusing more on how to increase the overall durability of response as well as increased the rate of response. And I think that’s going to be done by combining drugs. We have several active drugs now. So, figuring out how to combine them, and probably trying to treat patients earlier in their disease course will be important, so they don’t even get to the point of becoming transfusion dependent. Several of those studies I think are going to happen over the next few years. And of course, there are other drugs that are being studied in phase I and phase II trials. Some of those hopefully will also lead to benefit to patients so that if we cannot cure the disease, we can for most patients at least improve their quality of life, make transfusions as least as possible, and also make sure they are out of the hospital and having a good quality of life.”

    Q: What does the presentation at ASCO mean to you?

    A: “It’s one of the most gratifying moments for a clinical investigator when we hear a trial we worked on is positive. The reason why we do clinical trials is to help our patients. So have a positive trial and especially with an agent that you have worked on for years, and you have been very involved in the trial for a long time, not only in accruing patients, but also in the design and the conduct and oversight of the study and to have a trial being positive, especially for a randomized phase III trial, is a very good feeling, and the day when you hear that the results are positive is a day that you tend to remember for a very long time because what you have worked on did not only help your own patients, but hopefully if the drug gets approved, it’s going to help many patients that you have not directly interacted with, which is I think is the most important mission of any clinical research. We are the face of the trial as clinical investigators, but we have a huge team here at Yale. A lot of coordinators, clinical research nurses, regulatory staff, and our nurse practitioners – all of them have been very important to the conduct of the trial here at Yale. This was a global study that happened in many countries, many centers, and it’s a coordinated effort. So we are presenting the data on behalf of everybody and hoping that the regulatory review will be successful, and we have another option for our patients.”

    Yale Cancer Center/Smilow Cancer Hospital

    Source link

  • ASCO: Luspatercept enables majority of patients with MDS to end reliance on blood transfusions

    ASCO: Luspatercept enables majority of patients with MDS to end reliance on blood transfusions

    ABSTRACT: 7003

    Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no longer require regular blood transfusions. Results from the Phase III COMMANDS trial, led by researchers at The University of Texas MD Anderson Cancer Center, were reported at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

    The study evaluated the efficacy and safety of first-line treatment with luspatercept, which enhances red blood cell maturation, compared with epoetin alfa, a therapy commonly used for low blood cell count, in transfusion-dependent patients with anemia due to very low- to intermediate-risk MDS.

    In this interim analysis, 58.5% of patients receiving luspatercept achieved the primary endpoint of independence from red blood cell transfusions compared to 31.2% of patients who received epoetin alfa. Within the first 24 weeks of treatment transfusion, 47.6% of luspatercept patients achieved transfusion independence versus 29.2% of patients receiving epoetin alfa. Additionally, 74.1% of patients who received luspatercept saw hematologic improvement in erythroid responses greater than eight weeks, compared to 51.3% of patients who received epoetin alfa.

    “Patients with myelodysplastic syndromes often experience anemia that requires frequent red blood cell transfusions,” said Guillermo Garcia-Manero, M.D., professor of Leukemia and lead investigator of the study. “In this study, we observed a significant improvement in patient red blood cell counts with luspatercept, representing a promising advance to enhance the lives of these patients.” 

    Myelodysplastic syndromes are a group of diseases in which the bone marrow doesn’t produce enough healthy blood cells, including red blood cells. Patients with MDS often experience symptoms such as anemia, fatigue, shortness of breath and increased vulnerability to infection.

    Because of the frequency of anemia, most patients require regular red blood cell transfusions. Some cases of MDS can progress to acute myeloid leukemia (AML). Luspatercept is a novel agent that enables late-stage red blood cell maturation. By targeting the TGF-β signaling pathway, luspatercept helps restore normal red blood cell creation.

    The trial enrolled 301 patients at 226 sites. Patients were randomized to receive subcutaneous luspatercept every three weeks or subcutaneous epoetin alfa weekly for 24 weeks. Patient characteristics were balanced across both treatment arms.

    Treatment-related adverse events of all grades occurred in 30.3% of patients in the luspatercept group and 17.6% in the epoetin alfa group. Eight patients (4.5%) that received luspatercept discontinued treatment due to treatment-related adverse events. AML progression was reported in four patients receiving luspatercept and five patients receiving epoetin alfa. The safety profile was consistent with previous studies of the drug.

    “These results show, for the first time, superior effectiveness of an innovative therapy over epoetin alfa,” Garcia-Manero said. “I am encouraged by these results, as luspatercept represents a transformative therapy that could become a new standard of care for patients with transfusion-dependent myelodysplastic syndromes.”

    The patients in this study continue to be followed long term to determine overall survival, time of transfusion independence and frequency of progression to AML.

    The study was funded by Bristol Myers Squibb. Garcia-Manero has worked in a consulting/advisory role for and received research support from Bristol Myers Squibb. A full list of co-authors and disclosures can be found here.

    University of Texas MD Anderson Cancer Center

    Source link

  • Weight Loss Before Afib Ablation Procedure Results in Improved Outcomes Among Obese Patients

    Weight Loss Before Afib Ablation Procedure Results in Improved Outcomes Among Obese Patients

    Newswise — Results from a new clinical trial found overweight and obese patients with persistent and paroxysmal atrial fibrillation (AF) who lose weight prior to a catheter ablation procedure have improved clinical outcomes. The study, led by researchers with UHealth – the University of Miami Health System and the Miller School of Medicine, identifies weight loss before undergoing an ablation procedure as a risk-factor reduction tool for AF patients. Findings were presented today as a late-breaking clinical trial during Heart Rhythm 2023. 

    AF is the most common type of arrhythmia. There are approximately 2.3 million people in the United States who have AF, with 160,000 new cases diagnosed every year. Catheter ablation is a frequently used treatment for people with arrhythmias that can’t be controlled by medication or with certain types of arrhythmias from the heart’s upper chambers.1 While catheter ablation is a common AF treatment option, researchers are continuously evaluating how to improve AF ablation patient outcomes. This trial sought to determine whether additional non-ablation therapy targets can be integrated into treatment plans for patients undergoing catheter ablation for persistent AF and paroxysmal AF. 

    In the study, 65 patients with BMI≥27 kg/m2 who opted for catheter ablation to treat AF were enrolled and randomized to a 3-month pre-ablation period of standard risk factor modification (RFM) or RFM plus Liraglutide. From the enrolled participants, there were 59 patients (age 62±9 years, 27% female) weighing 106.4±18.5 kg (BMI 36.1±5.8 kg/m2); 79% had persistent AF and 21% had paroxysmal AF with 85% having hypertension, 27% diabetes, and 44% obstructive sleep apnea. Patients with a <3% weight change prior to their ablation procedure were labeled as Group 1 and patients with a ≥3-10% weight change were classified as Group 2. 

    The results showed AF status from enrollment to 6 months post-ablation. Group 1 had 29 patients with 0.2±2.7% weight gain and Group 2 had 30 patients with 5.6±1.8% weight loss. Freedom from AF off antiarrhythmic drugs at 6 months was 61% in Group 1 versus 88% in Group 2 (Fisher’s Test p=0.046, OLR p=0.0431). For patients with persistent AF treated with ablation (including one whose AF resolved with weight loss), freedom from AF off antiarrhythmic drugs at 6 months was 61% in Group 1 versus 90% in Group 2 (Fisher’s Test p=0.058, OLR p=0.051) and at 12 months was 42% in Group 1 versus 81% in Group 2 (Fisher’s Test p=0.050, OLR p=0.038). 1 Catheter ablation. Catheter Ablation | Johns Hopkins Medicine. (2021, February 22) 

    “We are constantly evolving our approach to AF to identify new ways to prevent recurrence and improve long term outcomes. While we already know the impact weight can have on overall outcomes, we believe the magnitude of the effect during this study is quite striking and that the findings show that even moderate weight loss may lead to a positive effect, but further analysis incorporating the potential independent contribution of Liraglutide is necessary” said Jeffrey Goldberger, M.D., M.B.A, Director, Center for Atrial Fibrillation, Professor of Medicine & Biomedical Engineering at UHealth – the University of Miami health System and the Miami Miller School of Medicine. “We hope that our findings will encourage physicians to integrate weight loss and risk factor modification into their treatment plans for patients undergoing catheter ablation and drive even more research dedicated to finding additional supportive solutions for patients living with AF.” 

    The authors of this trial would like to see additional trials focused on assessing the role of weight and weight loss in improving AF ablation outcomes and potentially identifying novel procedural approaches.

    University of Miami Health System, Miller School of Medicine

    Source link

  • Annual UCLA Nursing Science and Innovation Conference

    Annual UCLA Nursing Science and Innovation Conference

     Wed, May 31, 2023

     8:00 AM to 4:30 PM

     UCLA Covel Commons

    Newswise — UCLA Health Nursing and School of Nursing will host its 19th Annual Nursing Science and Innovation Conference on May 31 at the UCLA Covel Commons. This day-long conference will showcase science-based discoveries, best practices and processes, and policy development. This year’s conference theme is “Translating Research into Practice and Policy” – and will include addresses from two nationally recognized nurse scientists.

    For more information on the conference and how to register, visit the website.

    UCLA School of Nursing

    Source link

  • TVT 2023 Late-Breaking Science Announced

    TVT 2023 Late-Breaking Science Announced

    Newswise — NEW YORK – May 12, 2023 – The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 15 Late-Breaking Clinical Science studies. An annual meeting featuring cutting-edge research and techniques for structural heart interventions, TVT will take place June 7-10, 2023, at the Phoenix Convention Center – West in Phoenix, Arizona.

    TVT has become the epicenter of innovation and collaboration in the structural heart arena over its 16-year history. The meeting brings together world-renowned experts and master operators to help translate novel discoveries into practical therapies for patients with valvular heart disease.

    TVT’s late-breaking clinical science will highlight the latest advances in transcatheter aortic valve replacement as well as mitral, tricuspid, and left atrial appendage occlusion therapies. Data from these trials will help guide the selection of patients who will benefit most from these procedures and help define optimal treatment strategies, tools, and techniques for new and emerging treatments.

    Thursday, June 8, 2023

    Late-Breaking Clinical Science I

    Mitral Valve Disease

    Innovation & Clinical Science, Room 106

    11:00 AM – 12:15 PM MST

    • Contemporary, Core-Lab Assessed, Acute Clinical Outcomes from 2000+ Patients with Mitral Regurgitation Treated with the 3rd and 4th Generation MitraClip™ Systems: Results from the EXPANDed Post Approval Studies
    • Longer-Term Clinical and Echocardiography Follow-up of Transcatheter Mitral Valve Replacement with the Trans-apical Intrepid System
    • Contemporary Outcomes of Transcatheter Transeptal Mitral Valve in Valve in the United States
    • Mitral Valve Repair versus Replacement after Transcatheter Edge-to-Edge Mitral Repair: Results from The CUTTING-EDGE Registry
    • Pressure Gradients and Mortality Following Transcatheter Mitral Valve in Valve and Valve in Ring

    Friday, June 9, 2023

    Late-Breaking Clinical Science II

    Aortic Valve Disease (TAVR)

    Innovation & Clinical Science, Room 106

    11:00 AM – 12:15 PM MST

    • 5 Year Outcomes of TAVI Patients with Prosthesis-Patient Mismatch
    • Transcatheter Aortic Valve Replacement Using a Balloon-Expandable Valve in Patients with Type-0 Bicuspid Aortic Valve Stenosis
    • Real-World Early Outcomes of Evolut FX Versus PRO+ Transcatheter Aortic Valve Replacement
    • Analysis of New Permanent Pacemaker Implantation in the PORTICO NG Study Utilizing the Intra-Annular, Self-Expandable Navitor™ Transcatheter Aortic Heart Valve
    • Three-Year Outcomes from the Evolut Low Risk TAVR Bicuspid Study

    Saturday, June 10, 2023

    Late-Breaking Clinical Science III

    Early Human Experiences – Mitral Valve Replacement Innovation

    Innovation & Clinical Science, Room 106

    • Innovalve First-in-Human TMVR Experience (TWIST FIH): Clinical Outcomes and Echocardiography Evidence for Reverse Remodeling
    • Early Human Experience with the Cephea Transseptal TMVR System in Complex Mitral Anatomies
    • Bioprosthetic Surgical Valves in Intermediate-risk Patients: 1-Year Outcomes of the PARTNER 3 Mitral Valve-in-Valve Study
    • AltaValve Early Feasibility Study: Preservation of Mitral Valve Physiology Using a Passive Fixation TMVR Device
    • Trans-septal Mitral Valve Replacement with HighLife Valve in a Patient with Moderate-Severe Mitral Regurgitation

    In addition to the 15 late-breaking science studies, TVT will feature:

    • More than 30 live cases from 13 leading academic medical centers in North America and Europe
    • Six tracks: Imaging, Left Atrial Appendage (LAA)/Patent Foramen Ovale (PFO), Heart Failure, Mitral, Tricuspid, and TAVR
    • Case-based sessions and hands-on training
    • Moderated poster presentations
    • And much more!

    Additional information on TVT is available at https://tvt2023.crfconnect.com/.

    About CRF

    The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 30 years, CRF has helped accelerate medical breakthroughs and educated doctors on the latest treatments for heart disease. CRF’s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team. For more information, visit www.crf.org.

    ###

    Cardiovascular Research Foundation (CRF)

    Source link

  • Surgical resection is associated with superior 5-year survival compared to stereotactic body radiotherapy for early-stage lung cancer in healthy patients

    Surgical resection is associated with superior 5-year survival compared to stereotactic body radiotherapy for early-stage lung cancer in healthy patients

    Newswise — Stereotactic body radiotherapy (SBRT) is being used increasingly in early-stage lung cancer.  Between 2012 and 2018, the proportion of otherwise healthy patients treated with SBRT increased from 15 to 26%.  

    A study at the Yale University School of Medicine looked at data from the National Cancer Database for this six-year period and compared the 5-year survival rates for patients who had surgical resection and patients who elected to have SBRT. Overall, 30,658 patients were identified, including 24,729 (80.7%) who underwent surgery and 5,929 (19.3%) treated with SBRT.

    In propensity-matched patients, survival favored SBRT for the first several months, but reversed after one year and long-term significantly favored surgical management (5-year survival 71.0% for surgery vs. 41.8% for SBRT). When the propensity-matched analysis was repeated to only include SBRT patients who had documented refusal of a recommended surgery, surgical management again had a superior 5-year survival with (71.4% vs. 55.9%).

    The increasing usage of SBRT in otherwise healthy individuals represents a potential loss in life years for patients with early-stage NSCLC. Among patients that are eligible for either treatment, long-term survival favors surgical management, particularly for patients with a health-related life expectancy exceeding two years.

    Brooks Udelsman, MD, will present this study looking at some of the reasons patients opt for SBRT, Monday, May 8, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    American Association for Thoracic Surgery (AATS)

    Source link

  • Clinical Outcomes of more than 500 Lung Transplants using Ex vivo Lung Perfusion: A Large-Volume, Single-Center Retrospective Analysis

    Clinical Outcomes of more than 500 Lung Transplants using Ex vivo Lung Perfusion: A Large-Volume, Single-Center Retrospective Analysis

    Newswise — To compare the outcomes of patients receiving lungs transplanted after undergoing ex vivo lung perfusion (EVLP) versus those transplanted conventionally at the Toronto General Hospital, Aadil Ali, PhD, and coauthors looked at 14 years of data from the Toronto Lung Transplant Database. 

    Patients were separated based on whether they received lungs that underwent EVLP or whether they were transplanted conventionally (controls). They were matched 1:1 based on medical diagnosis, recipient status, recipient sex, recipient age, BMI, donor age, and calendar year. The group found no differences in the incidence of Primary Graft Dysfunction (PGD) Grade 3 at 72h, post-transplant mechanical ventilation, post-transplant hospital length of stay, intensive care unit (ICU) length of stay, allograft survival analysis, and CLAD-Free survival analysis.

    Dr. Ali and his associates report that “EVLP has been successfully incorporated in our program for more than a decade and is an effective method to expand the organ donor pool without compromising post-transplant outcomes.”

    Dr. Ali will present the results of this study Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    American Association for Thoracic Surgery (AATS)

    Source link

  • Long-term Outcome of Patients with Peripheral Ground Glass Opacity Dominant Lung Cancer After Sublobar Resections

    Long-term Outcome of Patients with Peripheral Ground Glass Opacity Dominant Lung Cancer After Sublobar Resections

    Newswise — In 2011, Makoto Suzuki, MD, and a team of associates from across Japan embarked on a long-term study of the safety and efficacy of sublobar resections for ground-glass opacity–dominant (GGO) peripheral lung cancer. When the group began the study, the optimal mode of surgery for GGO–dominant peripheral lung cancer defined with thoracic thin-section computed tomography was speculated as sublobar resection but not proven. At that time, the planned sample size was 330 with the expected 5-year relapse-free survival of 98% and a threshold of 95%.

    Between May 2009 and April 2011, 333 patients were enrolled from 51 institutions in Japan (median age was 62 at registration) and followed until May 6, 2021. Among that group, sublobar resections were performed in 314 patients (258 wedge resections and 56 segmentectomies), conversion lobectomies were performed in 11 patients, and eight were ineligible.  

    At five years, the group concluded that sublobar resection with enough surgical margin offered sufficient local control and relapse-free survival for lung cancer clinically resectable N0 staged by thin-section computed tomography with 3 or fewer peripheral lesions 2.0 cm or less amenable to sublobar resection and with a consolidation tumor ratio of 0.25 or less.

    At 10 years, the group can now report the reintervention-free survival of 98.6% and the overall survival of 98.5% for the 314 patients with sublobar resections. It concludes that the long-term results from their study suggest that sublobar resection for peripheral GGO-dominant lung cancer patients is a surgical procedure that can fully cure them of the disease. The indication of other treatment options should be further investigated.

    Dr. Suzuki will present this study Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    American Association for Thoracic Surgery (AATS)

    Source link

  • Results of Early Monitoring of Circulating Tumor DNA in Resected Early-Stage Non-Small Cell Lung Cancer

    Results of Early Monitoring of Circulating Tumor DNA in Resected Early-Stage Non-Small Cell Lung Cancer

    Newswise — Among the questions that cancer patients ask following their surgeries are, “Will it come back? Do I need additional treatment?”

    Circulating tumor DNA (ctDNA) offers a possible tool for answering those questions. ctDNA found in the bloodstream comes from cancerous cells and tumors; and monitoring ctDNA in patients with resected early-stage non-small cell lung cancer (NSCLC) could aid in detecting and managing recurrence. 

    Aaron Dinerman, MD, Baylor University Medical Center, Baylor Scott & White System, and coauthors evaluated the impact of early real-world experience of monitoring ctDNA among these patients.

    Beginning in October 2021, post-operative ctDNA was monitored for all surgically resected NSCLC patients (76) at the Baylor Medical Center. Peripheral blood samples were collected for ctDNA at 3-month intervals. Of those 76 patients, eight were positive for ctDNA. Post-operative clinical care was altered for seven of the eight; five received an earlier surveillance CT scan, and six received early PET-CT scan. Six of the ctDNA-positive patients had a biopsy-proven recurrence and were directed into therapy; two have not demonstrated radiographic evidence of recurrence but were directed into earlier interval surveillance.

    The serial monitoring of ctDNA following resection of early-stage NSCLC resulted in early detection of recurrent cancer and led to early surveillance and/or unexpected medical oncology referral in seven of the eight patients with positive ctDNA. (One patient demonstrated recurrence [brain metastases] with a negative ctDNA level.) This study exemplifies the impact of ctDNA on surveillance and management in early stage resected NSCLC. Further multicenter studies are required to determine protocol-specific best practices. 

     

    Travis Martin, DO, of the University of North Texas Health Science Center, will present the results of this study and its implications Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    American Association for Thoracic Surgery (AATS)

    Source link

  • Apixaban vs. Warfarin in Patients with an On-X Mechanical Aortic Valve

    Apixaban vs. Warfarin in Patients with an On-X Mechanical Aortic Valve

    Newswise — Although the On-X aortic valve and apixaban have been approved for use by the U.S. Food and Drug Administration (FDA), they had not been approved to be used together. Between May 2020 and September 2022, the PROACT Xa randomized, multicenter, open-label trial compared the direct factor Xa inhibitor apixaban (Eliquis) with warfarin in patients with bileaflet carbon aortic valves.

    A total of 863 patients from 60 sites who were at least 3 months out from aortic valve replacement (AVR) were randomized 1:1 to receive apixaban 5 mg twice daily or warfarin with a target INR of 2–3. Enrolled patients had a median age of 56 years; 24% were female. Among participants, 46% had AVR in the 12 months prior to randomization, 17% had AVR along with an aortic root graft, and 16% were reoperations on the aortic valve. Most patients (93%) received 81 mg of aspirin daily with the assigned anticoagulant.

    The study was discontinued on Sept. 21, 2022, at the recommendation of the PROACT Xa Data and Safety Monitoring Board based on observed higher rate of thromboembolic events (valve thrombosis and thromboembolism) in patients randomized to apixaban than warfarin.

    Lars Svensson, MD, of the Cleveland Clinic, will present the results of this study Saturday, May, 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles, detailing the events that led to the discontinuation.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    American Association for Thoracic Surgery (AATS)

    Source link

  • Safety and Efficacy of Delaying Nighttime Lung Transplantation

    Safety and Efficacy of Delaying Nighttime Lung Transplantation

    Newswise — Lung transplantation is routinely performed at night because of the unpredictability of donor organ procurement. Late start-times for complex operations such as lung transplantation have been associated with adverse outcomes. There are numerous reasons that delaying transplantation to the morning is preferable: Rested teams perform better; the well-being of the entire team is affected by long after-hours work; and during the day, more help is available for any intraoperative complications. 

    But is it safe to wait? Can cross clamp and cold ischemia times be extended? How does delaying the surgery impact the outcomes?

    Samuel T. Kim and colleagues at the University of California Los Angeles hypothesized that for donors with cross clamp times occurring after 1:30 a.m., the recipient operation could be delayed until morning with acceptable outcomes. Consented adult lung transplant recipients from March 2018 to May 2022 with donor cross-clamp times between 1:30 a.m. and 5:00 a.m. were prospectively enrolled in this study (34 patients; Night cohort); and their skin incision times were set at 6:30 a.m. A control group was identified and included recipients of donors with cross clamp times occurring at any other time of day (68 patients; Day cohort).

    Dr. Kim and his team examined short- and medium-term outcomes, including early mortality, a composite of post-operative complications, lengths of stay (ICU and total), 1- and 3-yr survival,) and chronic lung allograft dysfunction at 3-years between the two groups. The results for each of these comparisons were statistically similar.

    The group concluded that lung transplant recipients with donor cross clamp times scheduled after 1:30 a.m. can have their operations delayed safely until 6:30 a.m. with acceptable outcomes. And in experienced lung transplant centers, adoption of such a policy may lead to alternative workflow and improved team well-being.

    Dr. Kim will present this study Saturday, May, 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    American Association for Thoracic Surgery (AATS)

    Source link

  • Non-elective CABG Outcomes are Adversely Impacted by COVID Infection, but not by Altered Processes of Care

    Non-elective CABG Outcomes are Adversely Impacted by COVID Infection, but not by Altered Processes of Care

    Newswise — As thoracic researchers consider the myriad effects of COVID-19, they are looking at the impacts of the disease on patients and treatments, as well as care and treatment during the pandemic. Emily Grimsley, MD, at the University of South Florida, and co-authors looked at the differential effects of COVID-19 active viral infection, viral convalescence, and altered care processes on coronary artery bypass grafting (CABG) outcomes.

    Using data from the National COVID Cohort Collaborative (N3C) about CABG cases between 2020 and 2022, the group looked at patients who had tested negative for COVID-19, tested positive less than two weeks prior to surgery (COVID-Active infection), and tested positive more than two weeks prior to surgery. For control data, they used data from the National Surgical Quality Improvement Program (NSQIP).

    The incidence of in-hospital mortality, 30-day mortality, and infectious complications were significantly higher in the COVID-Active cohort compared to the other two groups. Adjusted analyses indicated in-hospital mortality, 30- and 90-day mortality, and infectious complications were significantly greater in the COVID-Active group compared to COVID-negative patients. 

    Comparing the equivalent mortality data for pre-COVID and the N3C data for COVID-negative patients, Grimsley’s group concluded that although the processes of care were altered by the pandemic, patient mortality did not change for COVID-negative patients. Their results indicate it is the COVID-19 infection that caused worse outcomes. Per Dr. Grimsley, “Even though healthcare delivery was significantly altered during the pandemic, it did not negatively affect patient mortality after CABG. In line with various other studies, we did see that patients with active COVID-19 infection did have higher mortality than their COVID-negative counterparts.” The group proposes further study to define the optimal timing of CABG in those with recent COVID-19 infection.

    Dr. Grimsley will present the results of this study Saturday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    American Association for Thoracic Surgery (AATS)

    Source link

  • Disparities in Racial/Ethnic Representation and Salary among Academic Cardiothoracic Surgeons

    Disparities in Racial/Ethnic Representation and Salary among Academic Cardiothoracic Surgeons

    Newswise — The American Association for Thoracic Surgery (AATS) is committed to diversity, equity, and inclusion. A wealth of data has shown that diversity in the physician workforce improves patient care, safety, physician well-being, and innovation; and fair compensation is essential to culturing a diverse workforce.

    To learn more about how race and ethnicity are related to compensation, diverse group of academic cardiothoracic surgeons led by Cherie P. Erkmen, MD, of Temple University, looked at the racial and ethnic representation among academic cardiothoracic surgeons. The group also analyzed salaries of cardiothoracic surgeons based on race/ethnicity. 

    Dr. Erkmen and her team looked at cross-sectional data collected by Association of American Medical Colleges Faculty Data for U.S. Medical Schools, which reported academic rank, race/ethnicity, and mean and median compensation. Their analysis reveals low diversity in the cardiothoracic workforce, especially at the advanced academic rank of professor. Black/African American cardiothoracic surgeons had lower salary than their colleagues, a difference that persisted at all academic ranks. Hispanic/LatinX and Asian cardiothoracic surgeons at lower academic ranks also experienced salary disparity, but equal or greater salaries compared with their colleagues when achieving the academic ranks of associate professor or professor. According to Dr. Erkmen, “These data demonstrate that the relationship between race/ethnicity and compensation is complex. Future studies are needed to understand mechanisms of salary disparity.” Dr. Erkmen concluded, “Our profession and our patients will benefit from a diverse workforce. Hopefully our work will someday lead to the development of best practices for equitable compensation that will support all cardiothoracic surgeons.”

    Dr. Erkmen will present this study on Saturday, May 6, at the AATS 103rd Annual Meeting in Los Angeles.

     

    Ethnicitya                          Overall             Professors               Salary comparison b

    White                                  65%                  78%

    Asian                                  25.2%                15%                        71-102%

    Hispanic/Latino                    4.0%                  3%                         86-130%

    Black/African American        3.3%                  2%                         76-85%

    a1.5% were multiple/other race and 0.4% were American Indian/Alaskan Indian.

    bPercentage of the mean and median salary earned by White cardiothoracic surgeons.

     

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    American Association for Thoracic Surgery (AATS)

    Source link

  • The Early Outcome of Lung Transplantation from Donors who Tested Positive for COVID-19

    The Early Outcome of Lung Transplantation from Donors who Tested Positive for COVID-19

    Newswise — The effects of the COVID-19 pandemic have rumbled through every piece of society, and nowhere more dramatically than in the medical communities.

    Takashi Harano, MD, and colleagues at Keck Medicine, University of Southern California, analyzed lung transplantation data from April 2020 to June 2022, to identify the early outcomes for patients who received lungs from COVID-19–positive donors. 

    Of the 29,944 donors identified by the Organ Procurement and Transplantation Network/United Network for Organ Sharing during that time, 1,297 were COVID-19 positive (4.3%). Lungs were transplanted from 47 donors.

    The recipients of allografts from those 47 donors had higher Lung Allocation Scores and more frequently underwent double lung transplantation (43/47). The post-transplant length of hospital stay, needs of Extracorporeal membrane oxygenation at 72 hours after transplantation, and survival outcomes were comparable between the two groups.

    This study reports that carefully selected lung allografts from COVID-19–positive donors had comparable early post-transplant outcomes to the lung allografts from COVID-19-negative donors. 

    Dr. Harano will present the results of this study Saturday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    American Association for Thoracic Surgery (AATS)

    Source link

  • Air Quality and Lung Cancer in Wayne County, Mich.—a Large Urban/Suburban Study

    Air Quality and Lung Cancer in Wayne County, Mich.—a Large Urban/Suburban Study

    Newswise — Lung cancer is the most common cause of cancer-related deaths in North America. Although cigarette smoking remains the main risk factor for lung cancer development, the importance of environmental factors such as pollution and poor air quality is becoming increasingly recognized. Excessive exposure to air pollutants, frequently found in larger urban areas, can lead to negative health outcomes including lung cancer.

    To understand the relationship between specific environmental pollutants and lung cancer in a large urban county in Michigan, Hollis E. Hutchings, MD, and a research group out of the Henry Ford Health System in Detroit analyzed comprehensive lung cancer information and air pollution data encompassing more than three decades. The group investigated the spatial relationship of lung cancer incidence within Wayne County over time and used air pollutant data from the U.S. Environmental Protection Agency to analyze the relationship between pollutant levels and the incidence of lung cancer.

    The group identified 58,866 cases of lung cancer. There were three major clusters of lung cancer incidence in the county. The most intense clusters were in downtown Detroit and the heavily industrialized downriver area. Sulfur dioxide (SO2) had the strongest statistical correlation with lung cancer. Particulate matter 10 (PM10), nitric oxide (NO2), volatile organic compounds (VOCs) and ozone levels also had statistically significant correlations with incidence.

    Based on these data, the group suggests that resident health in areas with poor air quality may benefit from targeted interventions such as campaigns for lung cancer screening and reduction of pollutants. Residential history may also be important when counseling individual patients with lung disease.

    Dr. Hutchings will present the results of this study Sunday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    American Association for Thoracic Surgery (AATS)

    Source link

  • Valved Sano Shunt Improves Immediate Outcomes Following Norwood Operation for Hypoplastic Left Heart Syndrome

    Valved Sano Shunt Improves Immediate Outcomes Following Norwood Operation for Hypoplastic Left Heart Syndrome

    Newswise — Hypoplastic left heart syndrome (HLHS) is a birth defect that affects normal blood flow through the heart. As the baby develops during pregnancy, the left side of the heart does not form correctly. The Centers for Disease Control and Prevention (CDC) estimates that each year about 1,025 babies in the United States are born with hypoplastic left heart syndrome—about one out of every 3,841 babies each year. 

    Although HLHS outcomes have improved tremendously with staged surgical palliation and the technical and management refinements incorporated over time, the overall 5-year survival rate is ~65%. Considerable Stage I perioperative and interstage morbidity and mortality remain, despite refinements of the surgical technique of the Norwood procedure. Two options used to circumvent the birth defect are the Blalock-Taussig (BT) shunt, which connects the right subclavian artery to pulmonary artery, and the Sano shunt, which connects directly from the right ventricle to the pulmonary artery. Although many centers have adopted the Sano shunt because it solves some of the weaknesses of the BT shunt physiology and improves survival outcomes, it has several shortcomings.

    David Kalfa, MD, PhD, and associates at Columbia University Medical Center hypothesized that use of the Valved Sano (VS) during the Norwood Stage I operation would improve cardiac hemodynamics, stabilize end-organ function postoperatively, reduce cardiac events and reinterventions, and boost ventricular recovery during the initial Stage I hospitalization and interstage periods. The group reviewed 25 consecutive HLHS neonates who underwent a valved Sano (VS) Stage I operation using a femoral venous homograft and 25 consecutive HLHS neonates who underwent a standard non-valved Sano (NVS) between 2014 and 2022. Primary outcomes were ventricular function, tricuspid regurgitation, end-organ function, Sano and pulmonary artery (PA) reintervention, and survival at post-operative, discharge, interstage, and pre-Glenn time points. 

    This retrospective analysis indicates that the VS was associated with improved multi-organ recovery and hemodynamic stability resulting in fewer patients experiencing cardiac events, fewer PA reinterventions before Stage II, and enhanced ventricular function recovery during initial hospitalization following the Norwood operation. These beneficial associations exist without an accompanied increase in conduit reinterventions. These promising findings warrant increased use and study of the VS during the Norwood operation.

    Dr. Kalfa will present this study Saturday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    American Association for Thoracic Surgery (AATS)

    Source link

  • Roswell Park Nurses Share Their Innovative Practices at Oncology Nursing Society Annual Congress

    Roswell Park Nurses Share Their Innovative Practices at Oncology Nursing Society Annual Congress

    (PLEASE NOTE INDIVIDUAL EMBARGO TIMES BELOW)

    • New inpatient admission process designed by Transplant & Cellular Therapy team
    • Critical-care nurse rounding reduces rapid responses, codes
    • Nurses create tool to identify patients who would benefit from palliative care

    Newswise — SAN ANTONIO, Texas — Evidence-based practice changes led by nurses from Roswell Park Comprehensive Cancer Center will be highlighted at the 48th annual Oncology Nursing Society (ONS) Congress April 26-30, 2023, in San Antonio, Texas.

    Hector Tirado, BSN, AAS, CPhT, will present “Standardized Transplant and Cellular Therapy Patient Education Upon Admission,” describing a new admissions protocol developed by nurses for inpatients in Roswell Park’s Transplant and Cellular Therapy (TCT) Center. The protocol centers on a checklist designed to ensure consistency and comprehensiveness in every inpatient admission.

    “The admissions process can be very overwhelming,” explains Tirado, first author of the paper. “There are a lot of moving parts. We created a system to make the experience uniform and standardized so every patient is getting the same education. It’s a great tool.”

    “There is a lot that has to be communicated and documented when we’re admitting someone for transplant or cell therapy, because we know these patients will be admitted for at least 30 days,” adds Amanda Blackburn, BSN, RN, co-author of the paper. Although patients and their caregivers attend an orientation together prior to the patient’s admission, Blackburn says repeating some of the information during admission is essential because so much is introduced during the orientation. “It’s information overload. People can’t remember everything.

    “Research shows that repetition improves outcomes in patients. So we go over the timeline of what to expect: ‘This is your preconditioning chemotherapy. Here’s what to expect on Day 0, Day 7, Day 10, and at discharge.’ ”

    Tirado and Blackburn created the new admissions checklist as a project for their nursing residency training at Roswell Park. They began with an electronic survey distributed to TCT nurses in March 2022, using software to consolidate responses. After receiving input from their colleagues, the team sent nurses a first draft of the checklist and then revised it based on their feedback. The team developed a separate template for nursing aides who set up rooms for new TCT inpatients. The lists cover a range of instructions, from what to do if the patient has tested positive for COVID-19 to placing precautions signage on the door, verifying allergies and educating patients about how to use the call bell.

    The list also reminds nurses to encourage patients to use an incentive spirometer to clear mucus from their lungs to help prevent pulmonary infection. Blackburn notes that since the checklist became standard practice, she has noticed more patients using spirometers throughout their stay. “It helps prevent pneumonia, which is a big risk factor for our patients,” she says.

    Tirado notes that the team paid close attention to the language used for the patient-education sections of the tool. “That’s important because of healthcare literacy,” he says. “We need to use words that patients understand.”

    Blackburn adds that along with increased patient safety and comfort, the new protocol has resulted in an added benefit: “Our nurses are more confident while doing an admission.”

    Tirado will outline the new system and its impacts in a podium presentation (embargo lifts) Friday, April 28, from 3-4 p.m.

    Reducing rapid responses and codes through critical-care nurse rounding

    Today, most cancer treatment is provided on an outpatient basis. Inpatient care is required mostly for complex procedures, the administration of biotherapies and some types of chemotherapy, and dealing with treatment complications and symptom management. Michael Martonara, BSN, BS, RN, will discuss the implications of this need for a higher level of nursing care during a poster presentation, “The Effects of Proactive Critical-Care Nurse Rounding with High-Risk Patients in a Dedicated Cancer Hospital,” (embargo lifts) Thursday, April 27, from 6:10-6:20 p.m.

    Martonara, first author of the presentation, developed a proactive “SWAT” model of rounding at Roswell Park and successfully advocated for its funding, leading to a 12-hour-per-day increase in critical-care nurse staffing for high-risk patients at the 142-bed dedicated cancer hospital. Over a trial period of seven months, SWAT nurses rounded daily to each inpatient unit, where staff identified patients at risk of clinical deterioration and those discharged from critical care the previous day. The SWAT nurses then assessed those patients for needed interventions.

    Thanks to early intervention, the need for rapid responses involving staff outside the Critical Care Unit fell from 4.5 per 1,000 patient days in the seven months prior to the SWAT program to 3.5 in the seven months after the program began. Codes outside the Critical Care Unit, signaling that a patient was in medical distress, dropped from .48 per 1,000 patient days in the seven months before implementation to .16 in the following seven months. The reduction in rapid responses and codes resulted in less disruption and the use of fewer resources, the nurse researchers note.

    The poster presentation was co-authored by Andrew Storer, PhD, DNP, RN, NP-C, A, FAANP, Vice President and Deputy Chief Nursing Officer.

    Palliative care screening tool delivers multiple benefits

    Heather Huizinga, MSN, RN, OCN, Director of Nursing Professional Development, Professional Practice, and Research, assisted a team of nurse residents — Kayla Redmond, BSN, RN; Christina Haidar, BSN, RN; Evgenii Ryzhkov, BSN, RN; and Carly Andriaccio, AAS, RN — in creating a poster presentation about their independently designed screening process to identify patients who would benefit from palliative care. The team will present “Creation of a Nurse-Driven Palliative Oncology Screening Tool,” outlining the benefits of making early introduction to palliative care services the standard of care for oncology inpatients: reduced symptom burden, better communication with healthcare providers, reduced emotional distress and greater patient satisfaction.

    A nurse survey informed the development of the screening tool. The team’s pilot analysis in 18 inpatients identified that a majority would benefit from palliative and supportive care, but had not yet been scheduled for a consult based on existing assessment aids.

    “Many palliative care screening tools are not specific enough to triage the needs of oncology patients with metastatic disease,” the authors note in their presentation. “The final tool can appropriately discern medical and surgical oncology patients who could benefit from palliative care.”

    The poster presentation is scheduled for (embargo lifts) Friday, April 28, from 5:50-6 p.m.

    ###

    Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or [email protected].

    Roswell Park Comprehensive Cancer Center

    Source link